HomeNewsOpinionChina’s M&A diplomacy: Endgame or endless game?

China’s M&A diplomacy: Endgame or endless game?

Chinese companies have been trying to influence not only the production chains but also the value and supply chains to stand out in the global market, and be at the top of the food chain

July 06, 2020 / 12:36 IST
Story continues below Advertisement

India’s revised FDI policy sets out a clear target to protect the domestic industry from falling easy prey to a predatory investment by Chinese Inc. It is predatory because Chinese Inc showed a strong appetite for mergers and acquisitions (M&A), and in recent years, they have been indiscriminatingly binging on takeovers despite unforeseen results.

The Chinese are on top of the list as not only India but Anglo-American, European models have been defused by the new Chinese interventions, which are more disruptive than adventure if one can call so. On the one hand, when the status of Chinese public sector investments is under scrutiny internationally, private players are eying for a more market rhythm in the time of financial distress.

Story continues below Advertisement

Such an endgame in the form of M&A always existed. However, China’s imperceptive use let the M&A to acquire not only a fancy name of takeover diplomacy but a reputation of disruptors.

Amid the COVID-19 pandemic, the Chinese outbound M&A recorded a steady growth of $59.6bn via 946 deals in Q1 2020. This is not at an average score compared to several deals and the total investment figures. Some of the M&A activities in past three weeks show the consistency at which Chinese companies made headways in Australia, the United States, Japan, Germany, South Korea, Russia, Holland, including some usual suspects around such as Singapore, Hong Kong, Malaysia, and others from South East Asia, to name a few.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show